Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany

Inclusion Criteria: * Age ≥18 years as of study index date; the study index date is date of initiation of treatment with dapagliflozin * Patient received/receiving treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure (HF) and at timepoint of dapagliflozin initiation with: * preserved ejection fraction (HFpEF; EF≥50%) OR mildly reduced ejection fraction (HFmrEF; EF 41-49%) * OR reduced ejection fraction (HFrEF EF ≤40%) * Patient is enrolled within 14 to 90 days following initiation of dapagliflozin * Signed and dated informed consent prior to enrolment in the study Exclusion Criteria: * Patient should not be enrolled if he/she is less than 14 days or more than 90 days following initiation of dapagliflozin * Prior treatment with dapagliflozin or other SGLT2i treatment * Initiation of dapagliflozin outside of the local HF label * Diagnosis of Type 1 diabetes prior to enrolment * Current or planned participation in a clinical trial using an investigational medical product for treating HF * Patient is involved in the planning and/or conduction of the study * Hypersensitivity to dapagliflozin or to any of the excipients listed in the SmPC